{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:27:06Z","timestamp":1792708026905,"version":"4.5.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Bullous pemphigoid (BP) is the most common autoimmune bullous disease and represents a recognized cutaneous immune-related adverse event associated with immune checkpoint inhibitors (ICIs). Management of ICI-induced BP is challenging, as conventional systemic corticosteroids may interfere with antitumor immunity, highlighting the need for effective steroid-sparing therapies. We report a case series of four elderly male patients who developed BP during treatment with ICIs and were successfully managed with dupilumab, an interleukin-4 receptor alpha antagonist. The median age was 72 years, and BP onset occurred a median of 26 weeks after ICI initiation; nivolumab was the trigger drug in all cases. Diagnosis was established through clinical features, histopathology, direct immunofluorescence, and serological detection of IgG antibodies against BP180, including midportion epitopes in some patients. All patients obtained a sustained clinical remission on dupilumab, with a four-year follow-up showing no treatment-related adverse events, no BP relapse despite continued ICI therapy, and no cancer progression. Our findings support the use of dupilumab as a safe and effective steroid-sparing treatment for ICI-induced BP and suggest that non-NC16A BP180 epitopes may aid diagnosis in selected cases.<\/jats:p>","DOI":"10.3389\/fmed.2026.1798188","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:26:54Z","timestamp":1775017614000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target"],"prefix":"10.3389","volume":"13","author":[{"given":"Dario","family":"Didona","sequence":"first","affiliation":[{"name":"Rare Skin Diseases Center, Istituto Dermopatico dell'Immacolata IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feliciana","family":"Mariotti","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell'Immacolata IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pira","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell'Immacolata IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Didona","sequence":"additional","affiliation":[{"name":"Rare Skin Diseases Center, Istituto Dermopatico dell'Immacolata IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hertl","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Marburg, Klinik f\u00fcr Dermatologie und Allergologie","place":["Marburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Zenzo","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell'Immacolata IDI-IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/ddg.15174","article-title":"Pemphigus and pemphigoids: clinical presentation, diagnosis and therapy","volume":"10","author":"Didona","year":"2023","journal-title":"J Dtsch Dermatol Ges."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1208418","DOI":"10.3389\/fmed.2023.1208418","article-title":"Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience","volume":"10","author":"Merli","year":"2023","journal-title":"Front Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"adv00377","DOI":"10.2340\/00015555-3740","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/cancers17111845","article-title":"Interleukin-4 and\u221213 gene expression profiles in immune-related bullous pemphigoid indicate efficacy of IL-4\/IL-13 inhibitors","volume":"17","author":"Arnold","year":"2025","journal-title":"Cancers."},{"key":"B5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/bjd\/ljad149","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment","volume":"189","author":"Shipman","year":"2023","journal-title":"Br J Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/1346-8138.16428","article-title":"Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines","volume":"49","author":"Takamura","year":"2022","journal-title":"J Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jaad.2022.08.001","article-title":"A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes","volume":"87","author":"Bur","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jdcr.2024.11.033","article-title":"Immune checkpoint inhibitor induced bullous pemphigoid treated by dupilumab: a case series","volume":"57","author":"Bogdanski","year":"2024","journal-title":"JAAD Case Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"oyaf208","DOI":"10.1093\/oncolo\/oyaf208","article-title":"Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series","volume":"30","author":"Nykaza","year":"2025","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e010638","DOI":"10.1136\/jitc-2024-010638","article-title":"Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events","volume":"13","author":"Khattab","year":"2025","journal-title":"J Immunother Cancer."},{"key":"B11","doi-asserted-by":"publisher","first-page":"16786","DOI":"10.3390\/ijms242316786","article-title":"From molecular insights to clinical perspectives in drug-associated bullous pemphigoid","volume":"24","author":"de Nicolas-Ruanes","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1494294","DOI":"10.3389\/fimmu.2024.1494294","article-title":"Bullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230","volume":"15","author":"Mariotti","year":"2024","journal-title":"Front Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaad.2022.02.036","article-title":"Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study","volume":"87","author":"Salemme","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2012.09.012","article-title":"Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme linked immunosorbant assay","volume":"68","author":"Fairley","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e15125","DOI":"10.1111\/exd.15125","article-title":"Reactivity against the BP180 ectodomain in patients with bullous pemphigoid, mucous membrane pemphigoid, multiple sclerosis and Parkinson disease","volume":"33","author":"Tegtmeyer","year":"2024","journal-title":"Exp Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1798188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:26:56Z","timestamp":1775017616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1798188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":15,"alternative-id":["10.3389\/fmed.2026.1798188"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1798188","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1798188"}}